Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Andrews Research & Education Foundation and Vector Science and Therapeutics Announce Collaboration for the Clinical Evaluation and Development of Peptides for Sports Medicine and Regenerative Medicine Applications

      https://vectorscience.co/

      News provided by

      Vector Sciences & Therapeutics

      Nov 18, 2026, 07:30 ET

      Share this article

      Share this article


      Partnership brings together Foundation's expertise in research and physician education with Company's peptide formulation, pharma-grade manufacturing, and delivery capabilities

      Livestreamed media briefing featuring Dr. James Andrews and Tommy Thompson set for 11 a.m. CST today

      GULF BREEZE, Fla. and MEQUON, Wis., Nov. 18, 2026 /PRNewswire/ -- Vector Science and Therapeutics (TSXV: PAIN) ("Vector" or the "Company") – Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. Secretary of Health and Human Services, four-term Governor of Wisconsin, and current Chairman of Vector, today announced a collaboration between the Andrews Research & Education Foundation (AREF) and the Company to advance the clinical evaluation of peptides for physicians' use in the practice of sports medicine and regenerative medicine. This partnership between industry and the medical research community is the first of its kind in the United States focused on musculoskeletal applications of peptides and aligns with the current movement toward much-needed regulation of peptide manufacturing and distribution.

      As part of the collaboration, AREF and the Company will design and initiate clinical programs to evaluate the use of Vector's pharma-grade peptides for musculoskeletal applications, including approaches to accelerate repair of soft tissue following activity or injury; motivate muscle regeneration in the aging athlete, and mitigate the impact of degenerative osteoarthritis. AREF will contribute intellectual property and bench-top research from its staff at its Gulf Breeze facility, while Vector will formulate, supply, and test peptides for the clinical projects using current good manufacturing practice (cGMP) consistent with applicable quality and regulatory requirements. Vector will also contribute specialized delivery-system development, prototyping, scale-up, manufacturing development, supply, testing and analytical services in its new Mequon, Wis., facility.

      "Our goal is to bring rigorous research and clinical insight to important questions in sports and regenerative medicine," said Dr. Andrews, President and Chairman of the Board at AREF. "By combining the Foundation's research experience and clinical perspective with Vector's capabilities, we can pursue projects grounded in scientific merit, patient need, and evidence. We have always led the way in developing new procedures and medical technology to help our patients. The use of peptides in medical practice is innovation that requires attention now, and we want to work closely with Vector to see that this is handled properly."

      In addition, AREF and the Company will develop physician education programs focused on peptide best practices and protocols. The programs will include courses for sports medicine fellows and residents, grand rounds, and multiple symposia offered through AREF's expansive sports medicine network.

      "The peptide marketplace needs trust, and that trust must be built on evidence, education, and quality," said Mr. Thompson. "This collaboration creates a framework to bring together established sports medicine research expertise and disciplined peptide development and manufacturing practices. We believe that this winning combination can help move the field toward a more rigorous, evidence-based approach."

      Intellectual property developed through the collaboration, including new peptides, new medical applications, and intellectual property resulting from research and clinical trials, will be jointly owned by AREF and the Company. Vector will lead the commercialization of new products in alignment with its highly focused, direct-to-physician marketing activities.

      "The relationship with AREF represents a pivotal moment for Vector and the medical community," said Bill Jackson, CEO of Vector. "We bring a focus on supply integrity, manufacturing rigor, and quality assurance. Working with AREF enables us to build on these strengths through the collaborative initiatives to obtain clinical evidence, advance education, and bring innovation to medical practice just as Dr. Andrews has done for decades. Together, we aim to help establish a more trusted foundation for peptide development and contribute to the development of rigorous, evidence-based standards for this emerging area in sports medicine and regenerative medicine."

      Livestreamed Media Briefing Information

      Date: Wednesday, Nov. 18, 2026

      Time: 11 a.m. to 11:30 a.m. CST

      Format: Live Zoom event originating in Gulf Breeze, Fla.

      Pre-registration and event access: https://russopr.zoom.us/webinar/register/WN_N_YU_AHMT-yOZk4iSdK41w

      Speakers: Dr. James Andrews, Tommy Thompson, Bill Jackson, Dr. Adam Anz, Dr. Josh Hackel

      Discussion Moderator: Solomon Wilcots, sports broadcaster and former NFL player, team member of Russo Partners' Sports-Health Alliance

      Journalists and other audience members should use the Zoom link above to pre-register. Following registration, attendees will receive the information needed to access the live event.

      Media Interview Scheduling and Coordination

      Immediately following the briefing, from 11:30 a.m. CST until 12:30 p.m. CST on Wednesday, Dr. Andrews, Mr. Thompson, and other briefing participants will be available to conduct media interviews via Zoom or telephone. Interview requests and scheduling will be handled through the chat function during the Zoom event or by email using [email protected]. Journalists who are unable to conduct interviews during this window may request additional times, and Russo Partners will manage these requests individually.

      Media Access to B-Roll Video Package

      A broadcast-quality B-roll package is available to media outlets. Contact Vector's media team at [email protected] to obtain access online. The package consists of footage of Vector's manufacturing team at work in Mequon, Wis., and video soundbites about the collaboration from Dr. Andrews, Tommy Thompson, Bill Jackson, and Benjamin Nelson, Ph.D., Chief Operating Officer at Lyogenesis and Verlyrix.

      About Dr. James Andrews

      Over a career spanning more than five decades, Dr. Andrews has helped shape modern sports medicine through his work advancing arthroscopic surgical techniques and research into the prevention and treatment of knee, shoulder, and elbow injuries. Dr. Andrews co-founded the American Sports Medicine Institute and the Andrews Sports Medicine and Orthopedic Center in Birmingham, Alabama, and is the founder of Andrews Research and Education Foundation and the Andrews Institute in Gulf Breeze, Florida. Dr. Andrews is also the founder of Andrews Medicine. Dr. Andrews has played a leading role in research, education, and the development of sports medicine specialists. His patients have included Michael Jordan, Bo Jackson, Drew Brees, Roger Clemens, Jack Nicklaus, and John Smoltz. Dr. Andrews' contributions to medicine have been recognized through his induction into the Alabama Sports Hall of Fame and Louisiana Sports Hall of Fame, the LSU Alumni Hall of Distinction, and the National Athletic Trainers' Association President's Award, among other honors.

      About the Andrews Research & Education Foundation

      The Andrews Research & Education Foundation (AREF), based in Gulf Breeze, Fla., focuses on advancing musculoskeletal research, injury prevention, surgical skills training, and physical rehabilitation. AREF operates specialized facilities, including a Biomechanics Lab, a Regenerative Medicine Center, and a Surgical Skills Lab, to support clinical trials, educate the next generation of sports medicine fellows, and improve outcomes for youth athletes, active-duty military personnel, veterans, and the broader community.

      About Vector Science and Therapeutics Corp.

      Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing anatomically focused drug delivery technology and cGMP-manufactured Rx peptides for the sports medicine, regenerative medicine, pain management, and wound care markets. Vector's peptides are made with pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) from qualified suppliers and are produced under current Good Manufacturing Practice (cGMP) and ISO-certified quality systems.

      The Company's product and intellectual property portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies. Vector is headquartered in Mequon, Wis. For more information, visit https://vectorscience.co/. Follow Vector on LinkedIn and X.

      Cautionary Note Regarding Forward-Looking Information

      This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, but is not limited to, statements regarding the collaboration between AREF and the Company; the design, initiation, scope and conduct of research and clinical programs by AREF and the Company; the evaluation and potential use of the Company's peptides in sports medicine, regenerative medicine and musculoskeletal applications; the development of physician education programs, best practices and protocols relating to peptides; the Company's development, formulation, manufacture, testing, scale-up and supply of peptides and related delivery systems; the development and ownership of new intellectual property, peptides, medical applications and products arising from the collaboration; the Company's ability to commercialize any products or technologies resulting from the collaboration; the regulatory environment with respect to peptides and the potential for the collaboration to advance evidence-based approaches to peptide development and use in sports medicine and regenerative medicine.

      Forward-looking information is based on management's current expectations, estimates, forecasts, beliefs and assumptions, including assumptions regarding the ability of the parties to successfully carry out the contemplated research, clinical and education programs; the scientific and clinical merits of the peptides and technologies to be evaluated; the availability of sufficient funding, personnel, facilities and other resources to carry out the collaboration; the Company's ability to formulate, manufacture, test and supply peptides and related products in accordance with applicable quality and regulatory requirements; the ability of the parties to obtain any required ethics, regulatory or other approvals; the ability to successfully develop, protect and commercialize intellectual property and products resulting from the collaboration; and the continued cooperation of AREF and other researchers, physicians and third parties involved in the contemplated programs.

      Such forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, the risks that research, preclinical or clinical results may not support the safety, efficacy or intended use of any peptide, product or technology being evaluated; clinical programs may be delayed, modified or discontinued or may not produce the anticipated results; required regulatory, ethics or other approvals may not be obtained on anticipated terms or timelines, or at all; applicable laws, regulations or regulatory policies relating to peptides, compounded drugs or investigational products may change or be interpreted in a manner adverse to the Company; the Company may be unable to manufacture, supply or scale products in accordance with applicable specifications, quality standards or regulatory requirements; the parties may not successfully develop or protect intellectual property arising from the collaboration; products or technologies developed through the collaboration may not receive required regulatory approvals or achieve physician, patient or market acceptance; the Company may not have sufficient capital or other resources to carry out its contemplated development and commercialization activities; and other risks and uncertainties described in the Company's public disclosure documents available under its profile on SEDAR+ at https://www.sedarplus.ca.

      Readers should be aware that the peptides and potential applications to be evaluated under the collaboration may be investigational and have not necessarily been approved by applicable regulatory authorities for the uses under evaluation. The collaboration is intended to generate scientific and clinical evidence concerning such potential applications, and no assurance can be given regarding the results of such research or whether any product or application will receive regulatory approval or be successfully commercialized.

      Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. The forward-looking information contained in this news release is made as of the date of this news release, and the Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.

      Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

      Photo availability: Photographs of Dr. James Andrews, Tommy Thompson, Bill Jackson, and AREF's and Vector's facilities are available to media outlets upon request.

      SOURCE Vector Sciences & Therapeutics

      Modal title

      Also from this source

      Sports Medicine Pioneer Dr. James Andrews and Vector Chairman Tommy Thompson, former U.S. Secretary of Health and Human Services, to Announce Major Medical Development Involving Peptides

      Sports Medicine Pioneer Dr. James Andrews and Vector Chairman Tommy Thompson, former U.S. Secretary of Health and Human Services, to Announce Major Medical Development Involving Peptides

      Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. Secretary of Health and...

      Vector Science and Therapeutics Corp. Responds to HHS Secretary Kennedy's Call for a Regulated Peptide Marketplace

      Vector Science and Therapeutics Corp. Responds to HHS Secretary Kennedy's Call for a Regulated Peptide Marketplace

      Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today welcomed remarks by U.S. Health and Human Services Secretary...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.